Celltrion’s manufacturing ops figure in AstraZeneca buyout buzz

John Carroll

Rumors are swirling that may have its sights set on the Korean biosimilars maker, and a would give the British drugmaker–or any of its rivals–an established biologics plant in a strategic location, and one that's expanding, at that.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS